Loading stock data…
OGN
$13.29+0.04 (+0.30%)
Market ClosedLast close May 1
Organon & Co.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Organon & Co. in the Healthcare sector is trading at $13.29. The stock is currently near its 52-week high of $13.39, remaining 57.8% above its 200-day moving average. Technical signals show overbought RSI of 80 and bullish MACD crossover, explaining why OGN maintains its current momentum and trend strength. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 80) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.29
Potential Upside
81%
Whystock Fair Value$24.05
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Hold
Mean target$11.25-15.3%
Range$8.00 – $14.00
Fundamentals
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internatio...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.38B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
12.69
Beta
Defensive asset. Lower volatility than the S&P 500.
0.64
Div Yield
Strong income play. Yield provides a meaningful total return floor.
90.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
24.87%
Volume
Today's trading volume
9.11M
Recent News
Organon (OGN)’s Investors React Strongly as Sun Pharma Bets Big on Specialty Drug Expansion
After surging 119.70% so far in April, Organon & Co. (NYSE:OGN) secures a spot on our list of the mid-cap stocks with the highest gains in April. On April 26, 2026, Sun Pharmaceutical Industries confirmed that it would acquire Organon & Co. (NYSE:OGN), a U.S. drugmaker, in an all-cash transaction with an estimated value of […]
Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates
Pharmaceutical company Organon (NYSE:OGN) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 3.5% year on year to $1.46 billion. Its non-GAAP profit of $0.71 per share was 16.8% below analysts’ consensus estimates.
Jim Cramer Says “Organon’s Done” Upon a Caller’s Inquiry
Organon & Co. (NYSE:OGN) was among the stocks on Jim Cramer’s Mad Money radar as he discussed the recent sell-off in AI-related stocks. Mentioning that they own NVO shares, a caller inquired if they should sell them and start a position in OGN, and in response, Cramer said: No, Organon’s done. Organon’s been, got a […]
Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Organon (OGN) Q1 Earnings and Revenues Miss Estimates
Organon (OGN) delivered earnings and revenue surprises of -14.87% and -0.48%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?